Results 281 to 290 of about 54,594 (319)

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies

Biomolecules & Therapeutics
Bispecific antibodies represent a significant advancement in therapeutic antibody engineering, offering the ability to simultaneously target two distinct antigens.
Seong Min Choi, Ju-hee Lee, Soyeon Ko, Soon-Sun Hong, Hyo-Eon Jin   +4 more
semanticscholar   +1 more source

Catumaxomab: A bispecific trifunctional antibody

Drugs of Today, 2009
The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian, A, Kuemmel, M, Schmidt, A, Schmittel   +3 more
openaire   +2 more sources

Bispecific antibody therapy for lymphoma

Best Practice & Research Clinical Haematology
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard, Gottfried, von Keudell   +1 more
openaire   +2 more sources

Bispecific human IgG by design

Journal of Immunological Methods, 2001
A major obstacle facing the development of bispecific antibodies as therapeutics has been the formidable task of producing these complex molecules in sufficient quantity and purity for clinical trials. These production difficulties have been largely overcome with the advent of efficient methods for the secretion of designer bispecific antibody ...
openaire   +2 more sources

T-cell-engaging bispecific antibodies in cancer

The Lancet, 2023
N. Donk, S. Zweegman
semanticscholar   +1 more source

Introduction: bispecific antibodies

Journal of Immunological Methods, 2001
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Bispecific antibodies in oncology

Nature Reviews Drug Discovery, 2022
Arman, Esfandiari, Sorcha, Cassidy, Rachel M, Webster   +2 more
openaire   +2 more sources

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nature Medicine, 2020
N. Shah, Bryon D. Johnson, D. Schneider, F. Zhu, A. Szabo, C. Keever-Taylor, W. Krueger, A. Worden, M. Kadan, Sharon Yim, Ashley M Cunningham, M. Hamadani, T. Fenske, B. Dropulić, R. Orentas, P. Hari   +15 more
semanticscholar   +1 more source

The present and future of bispecific antibodies for cancer therapy

Nature reviews. Drug discovery
C. Klein, Ulrich Brinkmann, Janice M. Reichert, R. Kontermann   +3 more
semanticscholar   +1 more source

Bispecific T cell engager therapy for refractory rheumatoid arthritis

Nature Medicine
Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer   +19 more
semanticscholar   +1 more source